Abstract
Anti-angiogenesis gene therapy is considered a promising treatment for excessive vascularization. Mesenchymal stem cell (MSC)-based gene therapy may enhance the effect of anti-angiogenesis by maintaining a long therapeutic period in vivo. However, transduction efficiencies and transgene expression in MSC-based gene therapy should be improved. Here we report human placenta-derived MSC (HPMSC)-based gene therapy using a fiber-modified adenoviral vector carrying the kringle1-5 gene to maintain long-term survival and effectively suppress angiogenesis both in vitro and in vivo. HPMSCs infected by the adenoviral vector were transduced at high efficiency with a low multiplicity of infection, and the infected HPMSCs expressed exogenous kringle1-5 protein in vitro and in vivo. Infected HPMSCs were detected at 2 weeks in vivo by fluorescence imaging and immunohistochemistry of reporter gene expression. Importantly, the microvessel growth of aortic rings in vitro was inhibited by administration of infected HPMSCs expressing kringle1-5 protein (K1-5-HPMSCs) at day 6. In Matrigel plugs combined with K1-5-HPMSCs, microvessel density was decreased as detected by immunohistochemistry and blood flow was decreased as detected by the power Doppler contrast enhanced at day 14. The fiber-modified adenovirus is an effective gene vector for HPMSC-based gene therapy, which may be a promising strategy for cancer anti-angiogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Quesada AR, Muñoz-Chápuli R, Medina MA . Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev 2006; 26: 483–530.
Bodempudi V, Ohlfest JR, Terai K, Zamora EA, Vogel RI, Gupta K et al. Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors. Cancer Gene Ther 2010; 17: 855–863.
Kim KS, Kim DS, Chung KH, Park YS . Inhibition of angiogenesis and tumor progression by hydrodynamic cotransfection of angiostatin K1-3, endostatin, and saxatilin genes. Cancer Gene Ther 2006; 13: 563–571.
Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S . Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 2000; 60: 2190–2196.
Cao R, Wu HL, Veitonmäki N, Linden P, Farnebo J, Shi GY et al. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA 1999; 96: 5728–5733.
Cao Y . Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001; 33: 357–369.
Kode JA, Mukherjee S, Joglekar MV, Hardikar AA . Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy 2009; 11: 377–391.
Farquhar C, Marjoribanks J, Basser R, Hetrick S, Lethaby A . High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev 2005; 20: CD003142.
Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant 2008; 14: 59–66.
Volpers C, Kochanek S . Adenoviral vectors for gene transfer and therapy. J Gene Med 2004; 6 (Suppl(1): S164–S171.
Sheets RL, Stein J, Bailer RT, Koup RA, Andrews C, Nason M et al. Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inserts. J Immunotoxicol 2008; 5: 315–335.
Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320–1323.
Kawabata K, Sakurai F, Koizumi N, Hayakawa T, Mizuguchi H . Adenovirus vector-mediated gene transfer into stem cells. Mol Pharm 2006; 3: 95–103.
Olmsted-Davis EA, Gugala Z, Gannon FH, Yotnda P, McAlhany RE, Lindsey RW et al. Use of a chimeric adenovirus vector enhances BMP2 production and bone formation. Hum Gene Ther 2002; 13: 1337–1347.
Sakurai F, Kawabata K, Mizuguchi H . Adenovirus vectors composed of subgroup B adenoviruses. Curr Gene Ther 2007; 7: 229–238.
Yu L, Shimozato O, Li Q, Kawamura K, Ma G, Namba M et al. Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. Anticancer Res 2007; 27: 2311–2316.
Segerman A, Atkinson JP, Marttila M, Dennerquist V, Wadell G, Arnberg N . Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 2003; 77: 9183–9191.
Wang H, Li ZY, Liu Y, Persson J, Beyer I, Möller T et al. Desmoglein 2 is a receptor for adenovirus serotypes3, 7, 11 and 14. Nat Med 2011; 17: 96–104.
Knaän-Shanzer S, van de Watering MJ, van der Velde I, Gonçalves MA, Valerio D, de Vries AA . Endowing human adenovirus serotype 5 vectors with fiber domains of species B greatly enhances gene transfer into human mesenchymal stem cells. Stem Cells 2005; 23: 1598–1607.
Liu HX, Chu YZ, Lou G . Fiber-modified adenovirus can mediate human adipose tissue-derived mesenchymal stem cell-based anti-angiogenic gene therapy. Biotechnol Lett 2010; 32: 1181–1188.
In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 2004; 22: 1338–1345.
Brooke G, Rossetti T, Pelekanos R, Ilic N, Murray P, Hancock S et al. Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials. Br J Haematol 2009; 144: 571–579.
Barlow S, Brooke G, Chatterjee K, Price G, Pelekanos R, Rossetti T et al. Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev 2008; 17: 1095–1107.
Sabapathy V, Ravi S, Srivastava V, Srivastava A, Kumar S . Long-term cultured human term placenta-derived mesenchymal stem cells of maternal origin displays plasticity. Stem Cells Int 2012; 2012: 174328.
Tuve S, Wang H, Ware C, Liu Y, Gaggar A, Bernt K et al. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol 2006; 80: 12109–12120.
Conget PA, Minguell JJ . Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells. Exp Hematol 2000; 28: 382–390.
Dayoub H, Dumont RJ, Li JZ, Dumont AS, Hankins GR, Kallmes DF et al. Human mesenchymal stem cells transduced with recombinant bone morphogenetic protein-9 adenovirus promote osteogenesis in rodents. Tissue Eng 2003; 9: 347–356.
Knaän-Shanzer S, Van Der Velde I, Havenga MJ, Lemckert AA, De Vries AA, Valerio D . Highly efficient targeted transduction of undifferentiated human hematopoietic cells by adenoviral vectors displaying fiber knobs of subgroup B. Hum Gene Ther 2001; 12: 1989–2005.
Knaän-Shanzer S, van de Watering MJ, van der Velde I, Gonçalves MA, Valerio D, de Vries AA . Endowing human adenovirus serotype 5 vectors with fiber domains of species B greatly enhances gene transfer into human mesenchymal stem cells. Stem Cells 2005; 23: 1598–1607.
Mizuguchi H, Sasaki T, Kawabata K, Sakurai F, Hayakawa T . Fiber-modified adenovirus vectors mediate efficient gene transfer into undifferentiated and adipogenic-differentiated human mesenchymal stem cells. Biochem Biophys Res Commun 2005; 332: 1101–1106.
Jendelová P, Herynek V, UrdzÃková L, Glogarová K, Kroupová J, Andersson B et al. Magnetic resonance tracking of transplanted bone marrow and embryonic stem cells labeled by iron oxide nanoparticles in rat brain and spinal cord. J Neurosci Res 2004; 76: 232–243.
Stojanov K, de Vries EF, Hoekstra D, van Waarde A, Dierckx RA, Zuhorn IS . [18F]FDG labeling of neural stem cells for in vivo cell tracking with positron emission tomography: inhibition of tracer release by phloretin. Mol Imaging 2012; 11: 11–12.
Fu Y, Azene N, Xu Y, Kraitchman DL . Tracking stem cells for cardiovascular applications in vivo: focus on imaging techniques. Imaging Med 2011; 3: 473–486.
Gildehaus FJ, Haasters F, Drosse I, Wagner E, Zach C, Mutschler W et al. Impact of indium-111 oxine labelling on viability of human mesenchymal stem cells in vitro, and 3D cell-tracking using SPECT/CT in vivo. Mol Imaging Biol 2011; 13: 1204–1214.
Leong-Poi H . Molecular imaging using contrast-enhanced ultrasound: evaluation of angiogenesis and cell therapy. Cardiovasc Res 2009; 84: 190–200.
Zhang SJ, Wu JC . Comparison of imaging techniques for tracking cardiac stem cell therapy. J Nucl Med 2007; 48: 1916–1919.
Lin Y, Molter J, Lee Z, Gerson SL . Bioluminescence imaging of hematopoietic stem cell repopulation in murine models. Methods Mol Biol 2008; 430: 295–306.
Wu JC, Cao F, Dutta S, Xie X, Kim E, Chungfat N et al. Proteomic analysis of reporter genes for molecular imaging of transplanted embryonic stem cells. Proteomics 2006; 6: 6234–6249.
Masson V VE, Devy L, Grignet-Debrus C, Bernt S, Bajou K, Blacher S et al. Mouse aortic ring assay: a new approach of the molecular genetics of angiogenesis. Biol Proced Online 2002; 4: 24–31.
Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D'Amico G et al. Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc 2011; 7: 89–104.
Cattaneo MG, Pola S, Dehò V, Sanguini AM, Vicentini LM . Alprostadil suppresses angiogenesis in vitro and in vivo in the murine Matrigel plug assay. Br J Pharmacol 2003; 138: 377–385.
Hernot S, Klibanov AL . Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev 2008; 60: 1153–1166.
Kragh M, Hjarnaa PJ, Bramm E, Kristjansen PE, Rygaard J, Binderup L . In vivo chamber angiogenesis assay: an optimized Matrigel plug assay for fast assessment of anti-angiogenic activity. Int J Oncol 2003; 22: 305–311.
Furlow B . Contrast-enhanced ultrasound. Radiol Technol 2009; 80: 547S–561S.
Leong-Poi H . Molecular imaging using contrast-enhanced ultrasound: evaluation of angiogenesis and cell therapy. Cardiovasc Res 2009; 84: 190–200.
Acknowledgements
This work was supported by grants from Specialized Research Fund for the Doctoral Program of Higher Education (No. 20092307110018); The Key Program of the Heilongjiang Provincial Science and Technology Committee (No. GC10C302); Programs Foundation of the Department of Education of Heilongjiang Province (No. 12511330); Programs Foundation of the Affiliated Tumor Hospital of Harbin Medical University (No. JJZ2011-06); Programs Foundation of the First Affiliated Hospital of Harbin Medical University (No. 2013B19); Programs Foundation of the Department of Health Heilongjiang Province (No. 2012661); and Programs Foundation of Natural Science of the Heilongjiang (No. D201272).We thank Yong Wang (Esaote Shenzhen Medical Equipment) for the help in the contrast imaging of the Matrigel plug models.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Chu, Y., Liu, H., Lou, G. et al. Human placenta mesenchymal stem cells expressing exogenous kringle1-5 protein by fiber-modified adenovirus suppress angiogenesis. Cancer Gene Ther 21, 200–208 (2014). https://doi.org/10.1038/cgt.2014.19
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2014.19